Search Videos and More


Three of the World’s Top Research Institutions Join Forces to Drive Progress Against Pediatric Cancer News

Three of the World’s Top Research Institutions Join Forces to Drive Progress Against Pediatric Cancer

Large-scale collaboration will leverage each institution’s expertise and infrastructure to advance understanding of the biological basis of pediatric cancers, identify new vulnerabilities of these diseases and accelerate cures globally.
Study Shows That Genomic Tumor Profiling of Pediatric Tumors Can Enhance Clinical Care News

Study Shows That Genomic Tumor Profiling of Pediatric Tumors Can Enhance Clinical Care

Results of a study of molecular tumor profiling in young patients revealed a high rate of genetic alterations with potential for impacting clinical care, including clarifying diagnoses and treatment with matched, precision cancer drugs.
Dana-Farber/Boston Children's Again Named Top Pediatric Cancer Program News

Dana-Farber/Boston Children's Again Named Top Pediatric Cancer Program

U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center #1 in the nation in its 2022-23 Best Children's Hospitals report. Dana-Farber/Boston Children's has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking's inception, earning more #1 rankings than any other program.
Researchers Identify Promising Drug Target in Pediatric Neuroblastoma News

Researchers Identify Promising Drug Target in Pediatric Neuroblastoma

Dana-Farber scientists have now teased apart the relationship between the proteins EP300 and CBP — to discover that EP300 is critical for a high-risk form of pediatric neuroblastoma.
Dana-Farber/Boston Children’s Exceeds Expected Outcomes for Stem Cell Transplants News

Dana-Farber/Boston Children’s Exceeds Expected Outcomes for Stem Cell Transplants

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center was ranked as one of 15 transplant centers in the country that performed above the expected survival rate, according to a new report.
Genetic Testing, Precision Therapy Spell Success for Young Patient with Rare Syndrome News

Genetic Testing, Precision Therapy Spell Success for Young Patient with Rare Syndrome

In a recent case study in the New England Journal of Medicine, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center describe how a drug targeting the genetic roots of the patient’s condition — an agent based on Nobel Prize-winning research by a Dana-Farber scientist — has caused new tumors in the patient to shrivel, her high blood pressure and headaches to ease, and her polycythemia to relent.
FDA Approval Offers Hope For Prevention of Acute Graft-Versus-Host Disease News

FDA Approval Offers Hope For Prevention of Acute Graft-Versus-Host Disease

Based on a clinical trial led by Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, the FDA has approved abatacept for the prevention of GVHD. This approval will allow many more patients to safely and effectively undergo stem cell transplants, particularly patients of diverse ethnicities who have more difficulty finding appropriately matched donors.
Researchers Solve Mystery of Retinoic Acid’s Potency Against High-Risk Neuroblastoma News

Researchers Solve Mystery of Retinoic Acid’s Potency Against High-Risk Neuroblastoma

For decades, retinoic acid has been a key part of the arsenal against the childhood cancer neuroblastoma. For just as long, scientists have wondered exactly how it works.
Targeted Agent Shows Early Promise Against a Dangerous Infant Leukemia News

Targeted Agent Shows Early Promise Against a Dangerous Infant Leukemia

Leukemias involving reshuffling or rearrangement of the mixed lineage leukemia (MLL) gene, known as MLL-rearranged or MLL-r leukemias, account for 70 to 80 percent of acute leukemias in infants under one year old. In these blood cancers, a subset of acute myeloid and acute lymphoid leukemias (AML and ALL), the MLL gene breaks and reattaches to the wrong section of the chromosome.
Looking for Cancer’s Achilles Heel: The Pediatric Cancer Dependency Map News

Looking for Cancer’s Achilles Heel: The Pediatric Cancer Dependency Map

Thanks to developments in precision medicine, some adult cancers are now treated with designer drugs that target the genetic mutations that caused them. But most children with cancer have not reaped the same benefits. Unlike adult cancers, childhood cancers carry few genetic mutations.
Pediatric Fertility Preservation Program News

Pediatric Fertility Preservation Program

At Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, we value the importance of fertility and reproductive health as it relates to long-term quality of life. As treatment for childhood cancers and blood disorders have improved, more and more survivors are entering their reproductive years and thinking about starting families of their own. The fertility preservation team will work closely with patients’ primary care team to ensure that a fertility consultation takes place as a part of the patient’s comprehensive work-up.